

◆ Department of Continuing Medical Education ◆

**Conflict of Interest Disclosure and Resolution & Core Competencies
Southeastern Multidisciplinary Approaches to Cancer Symposium
July 23-26, 2025**

City of Hope takes responsibility for the content, quality, and scientific integrity of this CME activity.

City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME). As a fully accredited ACCME Category 1 CME credit provider, the Continuing Medical Education Department has in place policies and procedures which insure the balance, independence, objectivity and scientific rigor in all of its educational activities. City of Hope complies with the [Standards for Integrity and Independence in Accredited Continuing Education](#) of the (ACCME), which REQUIRE that all relevant disclosed conflicts of interest be mitigated prior to the educational activity.

To this end all faculty presenters who are in a position to control the content of an educational activity must identify any real or apparent conflict(s) of interest by disclosing to the Department of CME all relevant financial relationships¹ with any ineligible company². To comply with more intense scrutiny by accreditation agencies, should you disclose any relevant conflict of interest with an ineligible company, the content of your presentation must be peer reviewed prior to presenting. Presentations will be provided to participants as an e-syllabus or in a meeting handout, all relevant disclosures will be made known to participants prior to the start of the activity.

In furtherance of program impartiality, we request the use of generic drug names in your presentation as opposed to trade names. Under no circumstances will we accept trade names. Additionally, contents of your presentation must be based solely on scientific methods generally accepted by the medical community. Data will have been objectively selected from peer-reviewed literature and will be presented in an unbiased manner.

CORE COMPETENCIES

The American Board of Medical Specialties (ABMS) and the Accreditation Council of Graduate Medical Education (ACGME) have embarked on a joint initiative to quantify and evaluate a set of 6 physician core competencies by which the individual physician will be measured for Residency Certification, Board Certification and more recently, Maintenance of Certification (MOC). Individual hospitals and other health care delivery organizations will now also be evaluated by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) on their practice and demonstration of the 6 core competencies.

In brief, the actual term “core competencies” refers to those six abilities (competencies) that are central (core) to the practice of medicine, specifically: (1) Practice-Based Learning and Improvement, (2) Patient Care, (3) Systems-Based Practice, (4) Medical Knowledge, (5) Interpersonal and Communication Skills, and (6) Professionalism. To assist our conferees in demonstrating their completion of CME in the six core competencies, the educational content of each presentation will be noted by numbers 1-6 in the table below. CME certificates for this activity will reflect those core competencies addressed by the educational content of the overall conference.

| Conference Faculty | Commercial Interest | Conflict/ Resolution & Faculty Discussion of Off-Label Drugs | Core Competencies |
|------------------------------|---|---|-------------------|
| Bamidele Adesunloye, MD, MS | Consultant for Eisai, Exelixis & Pfizer. | The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: Actinium-225, Capivasertib, Ipatasertib</i> | 2 & 4 |
| Sabarish Ayyappan, MD | Consultant for Abbvie, ADC Therapeutics, Fate Therapeutics, Genmab, Iowa Oncology Society & Regeneron. On the Speaker's Bureau for Beigene, Genmab, & Peerview. | The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: Anitocabtagene autoleuce</i> | 1, 2, 3 & 4 |
| Regina Brigman-Lake, DNP, RN | I do not have any relevant financial relationships with any ineligible companies. | None | 2, 5 & 6 |
| Amy Y. Chen, MD, MPH | I do not have any relevant financial relationships with any ineligible companies. | None | 1, 2, 3 & 4 |
| Dennis E. Choat, MD | I do not have any relevant financial relationships with any ineligible companies. | None | 2 & 4 |
| Devika Das, MD, MSHQS | I do not have any relevant financial relationships with any ineligible companies. | None | 1, 4 & 5 |
| Shady Eldaif, MD | I do not have any relevant financial relationships with any ineligible companies. | None | 1 |

| Conference Faculty | Commercial Interest | Conflict/ Resolution & Faculty Discussion of Off-Label Drugs | Conference Faculty |
|-------------------------------------|---|---|---------------------------|
| Salman Eraj, MD, MBA | I do not have any relevant financial relationships with any ineligible companies. | None | 4 |
| Sarah Friend, MD | I do not have any relevant financial relationships with any ineligible companies. | None | 1, 2, 3, 4, 5 & 6 |
| Natalie Godbee, DO | I do not have any relevant financial relationships with any ineligible companies. | None | 1, 2, 3, 4, 5 & 6 |
| Kristin Higgins, MD | Consultant for AstraZeneca, Daiichi Sankyo & Picture Health. | The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. | 1, 2, 3 & 4 |
| Kimberly F. Kerstann, PhD | I do not have any relevant financial relationships with any ineligible companies. | | 1 |
| Beomjune Kim, DMD, MD | I do not have any relevant financial relationships with any ineligible companies. | None | 1 |
| Miriam Knoll, MD | I do not have any relevant financial relationships with any ineligible companies. | None | 1 & 5 |
| Clayton Stephen Lau, MD | I do not have any relevant financial relationships with any ineligible companies. | None | 1, 2, 3, 4, 5 & 6 |
| Daneng Li, MD | Consultant for AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Coherus, Eisai, Exelixis, Genentech, Merus; Transthera, & Trisalus; and Grant/Research Support from AstraZeneca. | The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. | Reviewer |
| Maurie Markman, MD | Consultant for GSK. | The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. | 1, 2, 3, 4 & 6 |
| Nathan J. Neufeld, DO | Consultant for Medtronic & Stryker. | The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. | 1 & 4 |
| Tolutope Oyasiji, MD, MHSA | I do not have any relevant financial relationships with any ineligible companies. | None | 1, 2, 3, 4, 5 & 6 |
| Leslie Popplewell, MD | I do not have any relevant financial relationships with any ineligible companies. | None | 1, 2 & 4 |
| Vinod Pullarkat, MD | Consultant for Novartis, Jazz, Sanofi, Abbvie & Cogent. | The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. | 1, 2 & 4 |
| Delia Radovich, MD | I do not have any relevant financial relationships with any ineligible companies. | None | 2, 3, 4, 5 & 6 |
| Tulio Rodriguez, MD | On the Speakers Bureau for GSK & Sanofi. | The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. | 4 |
| Irati Rodriguez Matesanz, MSN, APRN | Consultant for AstraZeneca & Daiichi Sankyo. On the Speaker's Bureau for AstraZeneca & Daiichi Sankyo | The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. | 1, 3, 5 & 6 |

| Conference Faculty | Commercial Interest | Conflict/ Resolution & Faculty Discussion of Off-Label Drugs | Core Competencies |
|---|--|---|-------------------|
| Hope Rugo, MD | Consultant for BrBioNTech, Bristol Myers Squibb, Helsinn, and Nap. Grant/Research Support to UCSF from AstraZeneca, Ambryx, Daiichi Sankyo, Eli Lilly, F.Hoffman-LaRoche/Genentech, Gilead Sciences, Merck & Co., Novartis, Pfizer, Stemline Therapeutics; and Grant/Research from ALX Oncology, Bicycle Therapeutics, F.Hoffman-La Roche/Genentech, Mabwell, Merck & Co., Pfizer, PhoenixMD, Relay Therapeutics, & Stemline Therapeutics. | The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. | 1, 4 & 6 |
| Guilherme Sacchi de Camargo Correia, MD | I do not have any relevant financial relationships with any ineligible companies. | None | 2, 4 & 5 |
| Lily Shakibnia, MD, MSc | I do not have any relevant financial relationships with any ineligible companies. | None | 1, 2 & 4 |
| Nitika Sharma, MBBS, MD | I do not have any relevant financial relationships with any ineligible companies. | None | 2 & 4 |
| Kelly Tomlinson, DNP | I do not have any relevant financial relationships with any ineligible companies. | None | 5 |
| Graham Warren, MD, PhD | Consultant for Varian. | The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. | 1, 3, 4 & 6 |
| Kevin E. Woods, MD, MPH | I do not have any relevant financial relationships with any ineligible companies. | None | 1, 2, 3, 4, 5 & 6 |
| Kalemah Woolfolk, AGAC-NP, FNP | I do not have any relevant financial relationships with any ineligible companies. | None | 3, 5 & 6 |
| Jasmine M. Zain, MD | Grant/Research Support from Bioinvent, Dren Bio, Incyte, & Kiowa Kirin. | The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: DR-01, fenretinide, Darvalumab, CD70 bispecific, and CD5-CART</i> | 1, 2 & 4 |

1. The ACCME defines "relevant financial relationships" as financial relationships with an ineligible company (in any amount), occurring within the past 24 months, that create a conflict of interest.
2. The ACCME defines an "ineligible company" as any entity producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.